drugset / Trial / NCT00307398
Anecortave Acetate Risk-Reduction Trial (AART)
RandomizedParallel-groupDouble-blindTreatment
Summary
A 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.
Timeline
- Start
- 2004-03
- Primary completion
- 2009-01
- Completion
- 2009-01
Outcome
Outcome not reported
Stopped: “Management decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anecortave Acetate | Unknown | 15 mg | Other |
| Subject | Anecortave Acetate | Unknown | 30 mg | Other |